close

November 2017 VOL 8, NO 11

← Back to Issue


Category IV: Psychosocial Support, Assessment, Eighth Annual AONN+ Conference Abstracts

Quality of Life of Caregivers to Those Living with Chronic Myelogenous Leukemia

Ian Kudel, PhD1; Susan Gabriel, MS2; Erika Szabo, MPH, MSPharm2; Jifang Zhou, MD, MPH3; Ashutosh K. Pathak, MD, PhD, MBA, FRCP(Edin)2; Boxiong Tang, MD, PhD2; Nicola Brooksbank, BSN, RN, OCN4; Ryan Liebert, MS1
1Kantar Health, New York, NY
2Teva Pharmaceuticals, Frazer, PA
3University of Illinois at Chicago, College of Pharmacy, Chicago, IL
4Duke University Hospital, Durham, NC
 

Background: Research has consistently found that caregivers for people with cancer report distress; however, it is not clear whether recent improvements in the treatment of chronic myelogenous leukemia (CML) have reduced caregiver burden.

Objectives: In this study, the responses of caregivers with CML are compared with others, defined as those who care for people with other types of cancer (eg, breast cancer, lymphoma) and noncancer conditions (eg, Alzheimer’s) and noncaregivers, on a measure assessing function.

Methods: This study used data from 3 administrations (2012, 2013, 2015; n = 243,500) of the United States National Health and Wellness Survey, an Internet-based survey administered to a demographically representative sample of the US adult (≥18 years) population. Unique participants who supplied socioeconomic status, medical history, CML caregiver status, a comorbidity measure (Charlson Comorbidity Index), and behavioral data were included. All participants also responded to the Mental Component Scale (MCS), Physical Component Scale (PCS), and Short Form 6 Dimensions (SF-6D) of the 36-Item Short Form Health Survey, version 2. The minimally important difference (MID) is 3 points for the MCS and PCS, and 0.03 points for the SF-6D. Propensity score weights for caregivers of patients with CML (n = 49) and a second group (control group [CG]) composed of noncancer caregivers (n = 11,653), non-CML cancer caregivers (n = 2654), and noncaregivers (n = 182,246) were derived using the Toolkit for Weighting and Analysis of Nonequivalent Groups. Separate generalized linear models (GLMs) using a normal distribution with identity link functions were used for all the analyses.

Results: The GLM analyses found that the CML caregiver group demonstrated significantly worse functioning (P <.0001) across all outcomes. Further, the adjusted means between the 2 groups exceeded the MID for the MCS and SF-6D. The adjusted MCS mean was 39.74 (95% CI, 36.67-39.81) for the CML caregiver group and 46.39 (95% CI, 46.32-46.46) for the CG. The adjusted PCS mean was 47.07 (95% CI, 47.02-47.13) for the CML group and 49.79 (95% CI, 49.73-49.85) for the CG. Finally, the adjusted SF-6D mean was 0.62 (95% CI, 0.62-0.63) for the CML caregiver group and 0.71 (95% CI, 0.70-0.71) for the CG.

Conclusions: Analyses affirm that caregiving for those with CML is associated with poor self-reported health outcomes. These caregivers are reporting significantly greater distress than the control population despite recent improvements in treatment.

Related Articles
Category VI: Research, Quality, Performance Improvement, Eighth Annual AONN+ Conference Abstracts - November 3, 2017

Impact on Caregivers of Patients (Pts) with Myeloproliferative Neoplasms (MPNs) in the United States: Results from the Living with MPNs (LWMPN) Survey

Background: The MPNs myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are associated with a variety of burdensome symptoms (BMC Cancer. 2016;16:167) and reduced survival compared with the general [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts - November 3, 2017

Pooled Analysis of Safety with Extended 3-Year Follow-up Across Combination Dabrafenib and Trametinib (D+T) Phase 3 Trials

Background: Significantly improved outcomes with D+T vs BRAF inhibitor (BRAFi) monotherapy have been demonstrated in phase 3 BRAF V600E/K–mutant mel­anoma trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]), supporting use of D+T as [ Read More ]